Commentary

Article

State of the Science Summit - Gynecologic Cancers: Joshua G. Cohen, MD, FACOG, FACS

Author(s):

State of the Science Summit - Gynecologic Cancers: Joshua G. Cohen, MD, FACOG, FACS

State of the Science Summit - Gynecologic Cancers: Joshua G. Cohen, MD, FACOG, FACS

State of the Science Summit - Gynecologic Cancers: Joshua G. Cohen, MD, FACOG, FACS

Speakers

  • Joshua Cohen, MD | City of Hope
  • Ernest Han, MD, PhD | City of Hope
  • Thanh Dellinger, MD | City of Hope
  • Mihae Song, MD | City of Hope
  • Lorna Rodriguez-Rodriguez, MD, PhD | City of Hope

Topics

  • Gynecologic Cancer Care in a National Health System
  • Navigating PARP Inhibitors for Ovarian Cancer
  • Role of PIPAC in Gynecologic Cancer Treatment
  • Updates in Endometrial Cancer Treatment
  • Cellular Immunotherapy in Gynecologic Cancer: CAR-T and Beyond
  • ADCs and Future Directions in Ovarian Cancer
  • Clinical Scenarios in Gynecologic and Ovarian Cancer

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Related Videos
Domenica Lorusso, MD, PhD
Saro H. Armenian, DO, MPH
A panel of 3 experts on nasopharyngeal carcinoma
Saro H. Armenian, DO, MPH
Laura J. Chambers, DO
Angeles A. Secord, MD, MHSc
Idoroenyi Amanam, MD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.